An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.
- Author:
Akihiro SHIINA
1
;
Nobuhisa KANAHARA
;
Tsuyoshi SASAKI
;
Yasunori ODA
;
Tasuku HASHIMOTO
;
Tadashi HASEGAWA
;
Taisuke YOSHIDA
;
Masaomi IYO
;
Kenji HASHIMOTO
Author Information
- Publication Type:Clinical Trial ; Original Article
- Keywords: Schizophrenia; Sulforafan; Executive function; Clinical trial; CogState
- MeSH: Asian Continental Ancestry Group; Brassica*; Executive Function; Humans; Informed Consent; Learning; Mental Disorders; Outpatients; Oxidative Stress; Schizophrenia*; Tablets
- From:Clinical Psychopharmacology and Neuroscience 2015;13(1):62-67
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia. METHODS: We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8. RESULTS: A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants. CONCLUSION: This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.
